Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA) is the largest and most comprehensive cancer genomics study conducted in China. Our genome and epigenome roadmap of prostate cancer for Chinese men is consisted of over 1200 genomic datasets from more than 200 pairs of matched normal and primary prostate cancers, providing an invaluable resources and opportunity to complement and compare to previous cancer genomics studies represented by TCGA.
Alalysis Workflow | Sequencing Info | Somatic Alterations | Validation |
---|---|---|---|
DNA-seq | WGS | Somatic coding mutations (MAF File) Somatic CNV (Control-Freec、Gistic) Somatic SV (Meerkat Result) | FOXA1 Mutation Validation
SV Validation |
RNA-seq | Lnc-RNA Samll RNA | Fusion (SOAPfuse Result、General Result) | Fusion Validation |
DNA-methylation | WGBS | DMR (DMR Result) | - |
Study | Mutations | Fusions | CNAs |
---|---|---|---|
cpcg_2017 | + | ||
su2c_2015 | + | + | + |
mskcc_2017 | + | + | + |
wcm_2016 | + | + | |
broad_2013 | + | + | + |
broad_2012 | + | + | |
eururol_2017 | + | + | + |
fhcrc_nm_2016 | + | + | |
mskcc_2010 | + | + | |
mskcc_dfci_ng_2018 | + | + | + |
tcga_pub | + | + | + |
mskcc_2014 | + | ||
mskcc_cheny_2014 | + | ||
mich_2012 | + | + | + |